
BioLineRx (), or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the
NASDAQ Capital Market and on the
Tel Aviv Stock Exchange
The Tel Aviv Stock Exchange (TASE; ; colloquially known as The Bursa, ) is Israel's only public stock exchange and a public company that has been traded on the Tel-Aviv Stock Exchange since August 1, 2019. Legally, the exchange is regulated by ...
.
Corporate history
The firm was established in 2003 as a joint venture of
Teva
Teva is the Hebrew word for nature ( he, טבע, "nature").
Teva may refer to:
Companies
* Teva Footwear, American footwear manufacturer
* Teva Naot, Israeli footwear manufacturer
* Teva Pharmaceuticals, Israeli multinational pharmaceutical com ...
,
Hadasit Bio-Holdings, the
Jerusalem Development Authority, Yehuda Zisapel, and other investors. It executed an
initial public offering
An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors and usually also to retail (individual) investors. An IPO is typically underwritten by one or more investme ...
on the Tel Aviv Stock Exchange in February 2007, raising 211 million
NIS ($50 million) – the TASE's largest biotech IPO until that time. In July 2011 BioLine's
ADRs began trading on the NASDAQ Capital Market. In January 2012, the firm announced a deal with Genoscience, a French pharmaceutical company to jointly develop and market the BL-8020 compound, as a treatment for
Hepatitis C
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; it is a type of viral hepatitis. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, ...
. At the end of 2014,
Novartis
Novartis AG is a Swiss-American multinational pharmaceutical corporation based in Basel, Switzerland and
Cambridge, Massachusetts, United States (global research).name="novartis.com">https://www.novartis.com/research-development/research-loc ...
acquired a 12.8%
stake
Stake may refer to:
Entertainment
* '' Stake: Fortune Fighters'', a 2003 video game
* ''The Stake'', a 1915 silent short film
* "The Stake", a 1977 song by The Steve Miller Band from '' Book of Dreams''
* ''Stakes'' (miniseries), a Cartoon Netw ...
in the company as a strategic move to gain access to Israeli-sourced drug candidates.
Management
Morris Laster, (M.D.) an alumnus of.
Downstate Medical Center
SUNY Downstate Health Sciences University (Downstate) is a public medical school and hospital in Brooklyn, New York. It is the southernmost member of the State University of New York (SUNY) system and the only academic medical center for healt ...
, was
CEO
A chief executive officer (CEO), also known as a central executive officer (CEO), chief administrator officer (CAO) or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization especiall ...
of BioLineRx until 2009. He was replaced by
Kinneret Savitsky Kinneret is the English transliteration for Kineret, the Hebrew name of the Sea of Galilee, the largest freshwater lake in Israel.
Other meanings of Kinneret and Kineret include:
Places
* Camp Kinneret, a summer camp of Canadian Young Judaea
* Kin ...
, alumnus of
Tel Aviv University
Tel Aviv University (TAU) ( he, אוּנִיבֶרְסִיטַת תֵּל אָבִיב, ''Universitat Tel Aviv'') is a public research university in Tel Aviv, Israel. With over 30,000 students, it is the largest university in the country. Locate ...
early in 2010. Savitsky was replaced as CEO by BioLine COO Philip Serlin on October 10, 2016.
Operations
BioLineRx is a drug development company When promising compounds are discovered, the firm leads them through
preclinical trials and engages other companies to further develop them into commercializable drugs. The company entered into its first major commercialization agreement in 2009 when it partnered with Ikaria Holdings Inc. to develop its BL-1040 compound. In 2010, BioLine entered into a commercialization agreement with Cypress Bioscience Inc. for development of its BL-1020 compound. The agreement with Cypress was canceled in 2011 when the company was taken over by Ramius LLC.
Pipeline
Below is a partial list of drug compounds in various stages of
development by BioLineRx. Unless indicated otherwise, they have not obtained regulatory approval in relation to the diseases cited.
* BL-1010 – orally available
neuropathic pain
Neuropathic pain is pain caused by damage or disease affecting the somatosensory system. Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli ( allodynia). It may have continuo ...
*
BL-1020 – orally available
GABA-enhanced antipsychotic for treatment of
schizophrenia
Schizophrenia is a mental disorder characterized by continuous or relapsing episodes of psychosis. Major symptoms include hallucinations (typically hearing voices), delusions, and disorganized thinking. Other symptoms include social wi ...
* BL-1021 – orally available
small molecule
Within the fields of molecular biology and pharmacology, a small molecule or micromolecule is a low molecular weight (≤ 1000 daltons) organic compound that may regulate a biological process, with a size on the order of 1 nm. Many drugs are ...
for treatment of
neuropathic pain
Neuropathic pain is pain caused by damage or disease affecting the somatosensory system. Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli ( allodynia). It may have continuo ...
* BL-1040 – liquid polymer injected into patients with
acute myocardial infarction
A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops to the coronary artery of the heart, causing damage to the heart muscle. The most common symptom is chest pain or discomfort which may ...
, invented by Smadar Cohen of
Ben-Gurion University
* BL-1230 - a selective cannabinoid receptor type 2 (
CB2R) agonist for Dry Eye Syndrome (DES)
* BL-5010 – cream treatment for
seborrheic keratosis
A seborrheic keratosis is a non-cancerous ( benign) skin tumour that originates from cells, namely keratinocytes, in the outer layer of the skin called the epidermis. Like liver spots, seborrheic keratoses are seen more often as people age.
The t ...
skin lesions
* BL-7040 – orally available
anti-inflammatory drug
Anti-inflammatory is the property of a substance or treatment that reduces inflammation or swelling. Anti-inflammatory drugs, also called anti-inflammatories, make up about half of analgesics. These drugs remedy pain by reducing inflammation as ...
invented by
Hermona Soreq of the
Hebrew University of Jerusalem
* BL-8020 – orally administered treatment for Hepatitis C, developed by
Philippe Halfon, co-founder and President of Genoscience.
* BL-8030 – second-generation NS3
protease
A protease (also called a peptidase, proteinase, or proteolytic enzyme) is an enzyme that catalyzes (increases reaction rate or "speeds up") proteolysis, breaking down proteins into smaller polypeptides or single amino acids, and spurring the form ...
inhibitor for oral treatment of Hepatitis C, invented by
Philippe Halfon
See also
*
TA BlueTech Index
*
List of Israeli companies quoted on the Nasdaq
References
External links
BioJerusalemJerusalem Development Authority
{{Israel NASDAQ
Companies listed on the Tel Aviv Stock Exchange
Biotechnology companies established in 2003
Biotechnology companies of Israel
Companies listed on the Nasdaq
Drug discovery companies
2003 establishments in Israel